Table 2B.

MISCAN-Colon model: Results of the base-case and the sensitivity analyses for the Hemocult II strategy, the fecal immunochemical test (FIT) strategy and the new test strategy. The results are expressed per 1000 50-year-olds.

Strategy	No of CRC cases	Proportion of early stage CRC cases (UICC I and II), %	Reduction in CRC cases, %	No of CRC deaths	Reduction in CRC deaths, %	Discounted LYG	Discounted total costs, 1000 $
No screening	64.7	51	--	27.1	--	--	2,404
Base-case analyses
Hemoccult II	41.0	74	37	9.7	64	81	2,445
FIT	31.8	80	51	6.6	76	96	2,667
New test	42.2	83	35	7.9	71	91	2,979 (2,728) a
Sensitivity analyses
Test characteristics: Best case values (see Table 1A)
Hemoccult II	33.8	75	48	7.9	71	93	2,072
FIT	28.0	79	57	6.0	78	103	2,246
New test	42.2	83	35	7.7	71	93	2,979 (2,727) a
Test characteristics: Worst case values (see Table 1A)
Hemoccult II	37.9	71	41	9.8	64	75	2,672
FIT	31.8	78	51	7.0	74	90	2,813
New test	42.1	82	35	8.1	70	90	2,979 (2,728) a
Biennial screening interval
Hemoccult II	49.4	68	24	13.8	49	62	2,469
FIT	40.6	76	37	9.3	66	84	2,590
New test	52.1	78	19	11.3	58	78	2,895 (2,734) a
80% adherence with screening
Hemoccult II	47.8	68	26	13.5	50	64	2,448
FIT	40.1	72	38	10.3	62	79	2,614
New test	49.7	76	23	11.8	57	74	2,896 (2,674) a
50% adherence with screening
Hemoccult II	52.3	64	19	16.2	40	50	2,456
FIT	45.4	70	30	12.5	54	67	2,571
New test	54.8	72	15	14.3	47	62	2,825 (2,667) a

CRC = colorectal cancer; FIT = fecal immunochemical test; LYG = life-years gained compared with no screening

^aNumber in parentheses represents the result of the sensitivity analyses for the respective scenario when the unit cost of the new test was lowered from $24 to $0 (i.e., these are the total costs of the new test strategy when subtracting the costs attributable to the screening test itself.